[Side effects and safety of the new histamine H2 receptor antagonist ranitidine in the long-term treatment of patients with stomach and duodenal ulcers].
The safety and various side effects of ranitidine (2 X 150 mg daily), a new selective H2-receptor antagonist, were evaluated in the long-term treatment of patients with prepyloric or duodenal ulcer. A total of 6 adverse effects was reported by 5 out of 32 patients (18.7%). Thus, the overall incidence was low and almost half of the adverse effects involved minor or functional gastrointestinal symptoms. In no case were side effects severe enough to necessitate interruption of therapy. There were no detectable changes in haematological or biochemical blood parameters attributable to ranitidine. Long-term therapy with ranitidine appears to be safe and well tolerated; however, continued surveillance must be maintained.
D000293:Adolescent; D000328:Adult; D000368:Aged; D003248:Constipation / Q000139:chemically induced; D003967:Diarrhea / Q000139:chemically induced; D004381:Duodenal Ulcer / Q000188:drug therapy*; D005260:Female; D005663:Furans / Q000009:adverse effects* / Q000627:therapeutic use; D006261:Headache / Q000139:chemically induced; D006635:Histamine H2 Antagonists; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D011537:Pruritus / Q000139:chemically induced; D011899:Ranitidine; D013276:Stomach Ulcer / Q000188:drug therapy*
D005663:Furans; D006635:Histamine H2 Antagonists; D011899:Ranitidine
Nebenwirkungen und Sicherheit des neuen Histamin-H2-Rezeptor-Antagonisten Ranitidin in der Langzeitbehandlung von Patienten mit Ulcus ventriculi und duodeni.